secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001297184-23-000046
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q1 revenues $140M (+16% YoY); GAAP EPS $0.50, adj. EPS $0.62
----------------------------------------------------------------------

- Net revenues $140.0M vs $120.4M YoY; GAAP net income $26.0M ($0.50 diluted EPS).
- Adjusted non-GAAP net income $32.1M ($0.62 diluted EPS), up from $24.6M ($0.47) YoY.
- Key growth drivers: glucagon, Primatene MIST, epinephrine; new launches include regadenoson and intranasal naloxone.
- Proposed BAQSIMI acquisition noted as transformative for diabetes portfolio and branded product strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000046/0001297184-23-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000046/amph-20230509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-23-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer